{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:15Z","timestamp":1792801335591,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.metabol.2014.10.030","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T09:15:57Z","timestamp":1414746957000},"page":"S40-S46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":358,"special_numbering":"S1","title":["Biomarkers of Parkinson\u2019s disease: Present and future"],"prefix":"10.1016","volume":"64","author":[{"given":"Diane B.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2014.10.030_bb0005","first-page":"666","article-title":"The significance of defining preclinical or prodromal Parkinson\u2019s disease","volume":"27","author":"Olanow","year":"2012"},{"key":"10.1016\/j.metabol.2014.10.030_bb0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuint.2013.06.005","article-title":"Biomarkers in Parkinson\u2019s disease (recent update)","volume":"63","author":"Sharma","year":"2013","journal-title":"Neurochem Int"},{"key":"10.1016\/j.metabol.2014.10.030_bb0015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.nbd.2011.10.019","article-title":"Neurochemistry and the non-motor aspects of PD","volume":"46","author":"Ferrer","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.metabol.2014.10.030_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/bmm.13.139","article-title":"A \u2018bird\u2019s eye\u2019 view on the current status and potential benefits of blood biomarkers for Parkinson\u2019s disease","volume":"8","author":"Mielke","year":"2014","journal-title":"Biomark Med"},{"key":"10.1016\/j.metabol.2014.10.030_bb0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jns.2007.08.015","article-title":"Management of non-motor symptoms in advanced Parkinson disease","volume":"266","author":"Truong","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.metabol.2014.10.030_bb0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1212\/WNL.0000000000000243","article-title":"Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease","volume":"82","author":"Arkadir","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2014.10.030_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2014.10.030_bb0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1126\/science.1090349","article-title":"Looking backward to move forward: early detection of neurodegenerative disorders","volume":"302","author":"DeKosky","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.metabol.2014.10.030_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/bmm.09.10","article-title":"Searching for biomarkers of Parkinson\u2019s disease","volume":"3","author":"Scherzer","year":"2009","journal-title":"Biomark Med"},{"issue":"Suppl. 4","key":"10.1016\/j.metabol.2014.10.030_bb0050","first-page":"IV37","article-title":"Does levodopa slow or hasten the rate of progression of Parkinson\u2019s disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0055","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1474-4422(13)70047-4","article-title":"Chang the research criteria for the diagnosis of Parkinson\u2019s disease: obstacles and opportunities","volume":"12","author":"Berg","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/mds.25844","article-title":"Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson\u2019s disease","volume":"29","author":"Berg","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00702-013-1007-z","article-title":"Different diagnostic criteria for Parkinson disease: what are the pitfalls?","volume":"120","author":"Bhidayasiri","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.metabol.2014.10.030_bb0070","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson\u2019s disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2014.10.030_bb0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(13)70052-8","article-title":"Parkinson\u2019s disease redefined","volume":"12","author":"Deutch","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0080","first-page":"27","article-title":"Emerging candidate biomarkers for Parkinson\u2019s disease: a review","volume":"5","author":"Saracchi","year":"2014"},{"key":"10.1016\/j.metabol.2014.10.030_bb0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/bmm.10.93","article-title":"Biomarker research in Parkinson\u2019s disease: objective measures needed for patient stratification in future cause-directed trials","volume":"4","author":"Schlossmacher","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.metabol.2014.10.030_bb0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mds.25017","article-title":"Prerequisites to launch neuroprotective trials in Parkinson\u2019s disease: an industry perspective","volume":"27","author":"Streffer","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","article-title":"Cerebrospinal fluid biomarkers in Parkinson disease","volume":"9","author":"Parnetti","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1289\/ehp.1306967","article-title":"Research on the pre-motor symptoms of Parkinson\u2019s disease: clinical and etiological implications","volume":"121","author":"Chen","year":"2013","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.metabol.2014.10.030_bb0105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(13)70155-8","article-title":"The Harvard Biomarker Study\u2019s big plan","volume":"12","author":"Mohammadi","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2014.10.030_bb0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Paarkinson Progression Marker Initiative (PPMI)","volume":"95","author":"Marek","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0120","first-page":"483","article-title":"Biomarkers intersect with the exposome","volume":"17","author":"Rappaport","year":"2012"},{"key":"10.1016\/j.metabol.2014.10.030_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nbd.2010.04.020","article-title":"Diagnostic cerebrospinal fluid biomarkers for Parkinson\u2019s disease: a pathogenetically based approach","volume":"39","author":"Van Dijk","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.metabol.2014.10.030_bb0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12035-012-8291-8","article-title":"Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson\u2019s disease pathogenesis","volume":"46","author":"Yadav","year":"2012","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.metabol.2014.10.030_bb0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","article-title":"Pathogenesis-targeted, disease-modifying therapies in Parkinson disease","volume":"11","author":"AIDakheel","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.metabol.2014.10.030_bb0140","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.22432","article-title":"Neuroprotection trials in Parkinson\u2019s disease: systematic review","volume":"24","author":"Hart","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/mds.24997","article-title":"Trial designs used to study neuroprotective therapy in Parkinson\u2019s disease","volume":"28","author":"Lang","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/138920021502140327175404","article-title":"Genomic and pharmacogenomic biomarkers of Parkinson\u2019s disease","volume":"15","author":"Alonso-Navarro","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.metabol.2014.10.030_bb0155","doi-asserted-by":"crossref","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.metabol.2014.10.030_bb0160","doi-asserted-by":"crossref","first-page":"a009449","DOI":"10.1101\/cshperspect.a009449","article-title":"Genomics and bioinformatics of Parkinson\u2019s disease","volume":"2","author":"Scholz","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2014.10.030_bb0165","first-page":"S27","article-title":"Genomic and proteomic biomarkers for Parkinson disease","volume":"72","author":"Gasser","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2014.10.030_bb0170","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2217\/bmm.10.84","article-title":"Problems associated with fluid biomarkers for Parkinson\u2019s disease","volume":"4","author":"Nyhlen","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.metabol.2014.10.030_bb0175","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.0000000000000204","article-title":"Submandibular gland needle biopsy for the diagnosis of Parkinson disease","volume":"82","author":"Adler","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2014.10.030_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/CCLM.2011.077","article-title":"\u03b1-Synuclein in Parkinson disease and other neurodegenerative disorders","volume":"49","author":"Eller","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.metabol.2014.10.030_bb0185","first-page":"1","article-title":"Multiple organ involvement by alpha-synuclein pathology in Lewy Body disorders","volume":"00","author":"Gelpi","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0190","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mds.25789","article-title":"Alimentary, my dear Watson? The challenges of enteric \u03b1- synuclein as a Parkinson\u2019s disease biomarker","volume":"29","author":"Visanji","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0300","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0b013e3182a9f449","article-title":"\u03b1-Synuclein in cutaneous autonomic nerves","volume":"81","author":"Wang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2014.10.030_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standarize preanalyticl confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/j.metabol.2014.10.030_bb0205","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1586\/erm.10.86","article-title":"Exploiting the potential of molecular profiling in Parkinson\u2019s disease: current practice and future probabilities","volume":"10","author":"Mellick","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.metabol.2014.10.030_bb0210","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(08)70239-4","article-title":"Transcranial sonography in movement disorders","volume":"7","author":"Berg","year":"2008","journal-title":"Lancet Neurol"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2014.10.030_bb0215","first-page":"S656","article-title":"When does Parkinson\u2019s disease begin?","volume":"24","author":"Gaig","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0220","first-page":"001","article-title":"Magnetic resonance imaging (MRI) in Parkinson\u2019s disease","volume":"S1","author":"Tuite","year":"2013","journal-title":"J Alzheimers Dis Res"},{"key":"10.1016\/j.metabol.2014.10.030_bb0225","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1586\/ern.12.75","article-title":"Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson\u2019s disease","volume":"12","author":"Poewe","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.metabol.2014.10.030_bb0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fnhum.2014.00063","article-title":"Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson\u2019s disease using anatomic likelihood estimation","volume":"8","author":"Shao","year":"2014","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.metabol.2014.10.030_bb0235","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.24985","article-title":"Defining at-risk populations for Parkinson\u2019s disease: lessons from ongoing studies","volume":"27","author":"Berg","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0240","doi-asserted-by":"crossref","first-page":"e92878","DOI":"10.1371\/journal.pone.0092878","article-title":"Mild parkinsonian signs in the elderly \u2014 is there an association with PD? Crossectional findings in 992 individuals","volume":"9","author":"Lerche","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.metabol.2014.10.030_bb0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000353560","article-title":"Evaluation of progression markers in the premotor phase of Parkinson\u2019s disease: the progression markers in the premotor phase study","volume":"41","author":"Liepelt-Scarfone","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.metabol.2014.10.030_bb0250","first-page":"1","article-title":"PREDICT-PD: identifying risk of Parkinson\u2019s disease in the community: methods and baseline results","author":"Noyce","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.metabol.2014.10.030_bb0255","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.maturitas.2013.05.019","article-title":"Drug development in Parkinson\u2019s disease: from emerging molecules to innovative drug delivery systems","volume":"76","author":"Garbayo","year":"2013","journal-title":"Maturitas"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2014.10.030_bb0260","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1353-8020(11)70006-2","article-title":"Vaccination for Parkinson\u2019s disease","volume":"18","author":"Schneeberger","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.metabol.2014.10.030_bb0265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on a-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2014.10.030_bb0270","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1093\/brain\/awr015","article-title":"Salivary a-synuclein and DJ-1: potential biomarkers for Parkinson\u2019s disease","volume":"134","author":"Devic","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.metabol.2014.10.030_bb0275","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/brain\/awm304","article-title":"Metabolomic profiling to develop blood biomarkers for Parkinson\u2019s disease","volume":"131","author":"Bogdanov","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.metabol.2014.10.030_bb0305","doi-asserted-by":"crossref","DOI":"10.1289\/ehp.1308015","article-title":"The blood exposome and its role in discovering causes of disease","author":"Rappaport","year":"2014","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.metabol.2014.10.030_bb0285","doi-asserted-by":"crossref","first-page":"e94839","DOI":"10.1371\/journal.pone.0094839","article-title":"Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer\u2019s and Parkinson\u2019s diseases correlate with disease status and features of pathology","volume":"9","author":"Burgos","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.metabol.2014.10.030_bb0290","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2013.6031","article-title":"Environmental exposures and the risk for Alzheimer disease","volume":"71","author":"DeKosky","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514003394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514003394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:05:50Z","timestamp":1758427550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514003394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0026049514003394"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.10.030","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of Parkinson\u2019s disease: Present and future","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}